Countries Australia
The newly-installed service functions like Google Maps, but has been specifically developed to work indoors with a 10 to 20 times higher accuracy than GPS ...
August 03, 2023 | News
After a successful raise Navi Medical Technologies has closed a $2.4 million round of funding, which included a $700,000 lead in...
August 03, 2023 | News
“As we continue our efforts to advance novel treatment options for patients with high-risk Stage IIB-IV melanoma, the initiation of the V940-001 Phas...
July 28, 2023 | News
Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung ca...
July 27, 2023 | News
HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's ...
July 26, 2023 | News
SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) is a Phase II Positron Emission Tomography (PET) imaging tr...
July 25, 2023 | News
Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platform TAMP enables localized, ...
July 25, 2023 | News
Advanced visualization and AI leader TeraRecon, a ConcertAI company, is excited to announce an expansion of its reseller and service agreement in Aust...
July 24, 2023 | News
Summary Total revenue up 21% quarter-on-quarter to $120.7M driven by global product sales Positive operating cash flow ($10.8M, an improvemen...
July 20, 2023 | News
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Com...
July 19, 2023 | News
- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop...
July 18, 2023 | News
XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdo...
July 17, 2023 | News
Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI in Greater China ...
July 06, 2023 | News
FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer Phase III trial design based on&n...
July 05, 2023 | News
Most Read
Bio Jobs
News